Last updated: September 3, 2026
Nilutamide is a mature, low-revenue androgen-receptor antagonist with limited commercial relevance in the current prostate-cancer market. Sanofi’s Nilandron was approved by the U.S. Food and Drug Administration in 1996 for use with surgical castration in metastatic prostate cancer. The product competes against newer androgen-receptor pathway inhibitors and has lost strategic importance because of its older mechanism, modest clinical differentiation, safety restrictions, and limited prescribing base.[1]
No reliable public source reports current standalone revenue for Nilandron or nilutamide. Sanofi’s financial disclosures aggregate products within broader pharmaceutical franchises and do not identify Nilandron as a material revenue contributor.[2] The financial trajectory is therefore best characterized as a decline from an older branded product to a niche or commercially inactive medicine, rather than as a growth asset.
What is nilutamide and how is it used?
Nilutamide is a nonsteroidal antiandrogen. It inhibits androgen-receptor signaling and was developed for hormone-sensitive treatment of metastatic prostate cancer, generally in combination with surgical castration.
The U.S. label specifies:
| Attribute |
Nilutamide |
| Brand |
Nilandron |
| Active ingredient |
Nilutamide |
| Original U.S. sponsor |
Roussel Uclaf, later associated with Sanofi |
| FDA approval |
1996 |
| Dosage form |
Oral tablet |
| Strengths |
50 mg and 150 mg tablets |
| Primary indication |
Metastatic prostate cancer with surgical castration |
| Pharmacologic class |
Nonsteroidal androgen-receptor antagonist |
| Key safety restrictions |
Interstitial pneumonitis, hepatotoxicity, visual adaptation problems, alcohol intolerance |
| Reference NDA |
NDA 020455 |
The labeled regimen begins with 300 mg daily for 30 days, followed by 150 mg daily.[1] The drug’s adverse-effect profile and clinical limitations restricted its competitive position against other hormonal therapies.
When did nilutamide lose market exclusivity?
Nilutamide’s core U.S. market exclusivity expired many years ago. The product was approved in 1996, and any ordinary small-molecule patent protection would have expired by the late 2000s or early 2010s, subject to patent-term adjustments, patent-term extensions, and jurisdiction-specific filings.
The commercial issue is no longer the timing of original patent expiry. Nilutamide is a legacy product facing therapeutic substitution and limited market demand. Its principal competitive barriers are clinical adoption, manufacturing economics, regulatory maintenance, and prescriber preference rather than enforceable exclusivity.
Does nilutamide have active Orange Book protection?
The FDA Orange Book should be reviewed for the current listing status of NDA 020455 and any associated patent or exclusivity entries.[3] Publicly available product information does not support a current, commercially meaningful patent barrier around nilutamide. Any historical listed patents would not be expected to provide a practical basis for delaying generic competition at this stage.
The Orange Book distinction between an NDA remaining in the database and a product remaining commercially available is important. A discontinued or rarely marketed reference product can retain historical regulatory records without generating meaningful branded sales.
What is the FDA regulatory status of Nilandron?
Nilandron received FDA approval for metastatic prostate cancer in 1996. Its label contains several restrictions that affected its commercial use:
- The drug is used with surgical castration rather than as a fully independent androgen-deprivation strategy.
- Pulmonary toxicity, including interstitial pneumonitis, is a significant warning.
- Hepatic injury and liver-function monitoring are relevant safety concerns.
- Delayed adaptation to darkness and other visual effects can affect patients.
- The product is not positioned as a modern first-line androgen-receptor pathway inhibitor.
FDA labeling also states that nilutamide does not eliminate the need for surgical castration. That requirement limits convenience compared with oral agents that are used within broader medical androgen-deprivation regimens.[1]
How does nilutamide compare with competing prostate-cancer drugs?
Nilutamide competes in a market that has shifted toward more potent and commercially supported agents.
| Drug |
Mechanism or pathway |
Commercial position |
| Nilutamide |
Nonsteroidal androgen-receptor antagonist |
Legacy, niche, or inactive branded product |
| Flutamide |
Older nonsteroidal antiandrogen |
Limited use because of toxicity and newer alternatives |
| Bicalutamide |
Nonsteroidal androgen-receptor antagonist |
Historically broader use; largely mature |
| Enzalutamide |
Androgen-receptor signaling inhibitor |
Major modern branded therapy |
| Apalutamide |
Androgen-receptor inhibitor |
Modern prostate-cancer franchise |
| Darolutamide |
Androgen-receptor inhibitor |
Modern agent with differentiated safety and combination use |
| Abiraterone |
CYP17 inhibitor that suppresses androgen synthesis |
Broad historical commercial use, including generic competition |
| Relugolix |
Oral GnRH receptor antagonist |
Medical castration alternative with differentiated administration |
Enzalutamide, apalutamide, darolutamide, abiraterone, and relugolix have stronger contemporary commercial profiles because they support modern treatment pathways, broader disease-stage positioning, or more convenient medical management. Nilutamide’s use with surgical castration and its safety profile reduce its addressable market.
How many patents cover nilutamide?
Nilutamide is not a current high-value patent estate. Historical patent families may have covered the active compound, synthesis, pharmaceutical compositions, and therapeutic use. Those rights would generally be expired or commercially immaterial in the United States and other major pharmaceutical markets.
No current public evidence indicates a meaningful portfolio of unexpired U.S. composition-of-matter, formulation, or method-of-use patents capable of supporting premium pricing. The product therefore differs from newer prostate-cancer medicines whose revenue depends on extended patent estates, pediatric extensions, new indications, or formulation strategies.
What formulations are protected by nilutamide patents?
Nilutamide is supplied as an oral tablet. There is no widely recognized current formulation franchise comparable with long-acting injectables, modified-release products, depot formulations, or delivery-system patents. The tablet dosage form is technically straightforward and does not create a strong manufacturing barrier.
Any remaining formulation rights would have to be assessed through current patent registers and national prosecution records. They are unlikely to alter the product’s commercial profile because the active ingredient is old, the dosage form is conventional, and clinical substitution is strong.
Are there Paragraph IV challenges or generic entry risks?
The principal generic-entry risk has already materialized in economic terms because the product’s ordinary exclusivity period has ended. A Paragraph IV challenge would have limited strategic value unless a generic applicant identified sufficient demand to justify formulation, regulatory, and distribution costs.
For nilutamide, the relevant generic scenarios are:
- An existing generic supplier continues limited supply in selected markets.
- A new manufacturer enters only if procurement demand or a shortage creates pricing room.
- The reference product becomes unavailable while physicians substitute other antiandrogens or modern agents.
- A generic launch produces little revenue because the market has shifted away from nilutamide.
Small-molecule generics do not create biosimilar risk. Nilutamide is chemically synthesized, not a biologic, so FDA abbreviated new drug application procedures, rather than biosimilar approval pathways, are relevant.[4]
What patent litigation affects nilutamide?
Nilutamide does not appear to have a current litigation profile comparable with major oncology products. There is no widely reported recent U.S. patent dispute involving Nilandron that materially affects market access, launch timing, or valuation.
Historical litigation risk would have centered on:
- Compound and composition-of-matter patents.
- Generic certification under Paragraph IV.
- Labeling or method-of-use claims.
- Patent listing disputes involving the Orange Book.
- Supply and discontinuation issues rather than infringement damages.
The absence of current litigation is consistent with an expired or commercially weak patent estate.
What licensing deals involve nilutamide?
Nilutamide originated with Roussel Uclaf and became associated with the Sanofi organization through corporate consolidation. Public company reporting does not identify a current licensing deal for nilutamide as a material commercial asset.
The product’s corporate history matters because rights, manufacturing responsibilities, and regulatory ownership may have moved through mergers or portfolio transfers. Those transactions do not indicate current economic value. No publicly disclosed recent transaction assigns a meaningful standalone valuation to nilutamide.
What is nilutamide’s financial trajectory?
Nilutamide’s revenue trajectory follows the standard lifecycle of a legacy oncology product:
| Period |
Commercial condition |
Financial implication |
| 1990s |
Newly approved antiandrogen |
Initial branded opportunity |
| 2000s |
Mature product with older-generation competition |
Pricing and volume pressure |
| 2010s |
Generic and therapeutic substitution |
Declining branded relevance |
| 2020s |
Limited or discontinued commercial role |
No publicly reported material standalone revenue |
Sanofi’s annual reports do not provide a separate Nilandron revenue line.[2] The absence of product-level disclosure indicates that nilutamide is below the company’s materiality threshold or no longer an active commercial priority. It does not establish zero sales in every market.
What is the revenue exposure?
Revenue exposure is low for the originator and likely limited for any generic manufacturer. The product lacks the characteristics associated with durable pharmaceutical cash flow:
- No meaningful remaining patent exclusivity.
- No large current indication expansion.
- No high-growth treatment segment.
- No differentiated delivery system.
- No biologic manufacturing barrier.
- Strong substitution by newer androgen-receptor therapies.
- Limited public evidence of active branded promotion.
The more relevant financial risk is operational. A supplier may face low-volume manufacturing, batch-release costs, raw-material sourcing constraints, and discontinuation decisions. For hospitals and pharmacies, the principal risk is supply continuity rather than price escalation caused by patent exclusivity.
What generic launch scenarios exist for nilutamide?
A generic launch would be commercially viable only under narrow conditions. A manufacturer would need an approved formulation, reliable active-pharmaceutical-ingredient supply, and sufficient institutional or retail demand. The product could have temporary value during a shortage or where formularies require a low-cost legacy antiandrogen.
A broad branded-to-generic conversion is unlikely to create a large market because nilutamide is already therapeutically displaced. Physicians may switch patients to bicalutamide, abiraterone, enzalutamide, apalutamide, darolutamide, or another androgen-deprivation strategy instead of selecting nilutamide.
How strong is the nilutamide patent estate?
Nilutamide has a weak current patent estate from an investment perspective. Its historical composition-of-matter protection is old, and there is no evident modern patent layering around formulations, combinations, delivery systems, or new indications.
| Patent-estate factor |
Assessment |
| Core compound protection |
Historical and likely expired |
| Formulation protection |
No material current barrier publicly established |
| Method-of-use protection |
Limited commercial relevance |
| Manufacturing IP |
Potential process know-how, but not a major market barrier |
| Regulatory exclusivity |
Expired |
| Biosimilar protection |
Not applicable |
| Litigation leverage |
Low |
| Generic deterrence |
Low |
Geographic differences may remain. Some countries may have no active commercial supply, while others may retain limited generic availability. Those differences reflect registration and distribution economics rather than a durable global exclusivity strategy.
Key Takeaways
- Nilutamide is a legacy oral antiandrogen approved by the FDA in 1996.
- Nilandron’s principal indication is metastatic prostate cancer used with surgical castration.
- Its original exclusivity period has expired, and current patent protection does not appear commercially significant.
- No reliable public source reports standalone nilutamide revenue.
- Sanofi’s financial disclosures do not identify Nilandron as a material revenue contributor.
- Generic entry risk is technically high but economically limited because therapeutic substitution has reduced demand.
- Biosimilar risk does not apply because nilutamide is a small-molecule drug.
- The main commercial risks are discontinuation, supply constraints, and substitution by newer prostate-cancer therapies.
- Nilutamide has low current strategic value for originators, licensors, and patent investors.
FAQs
Is Nilandron still sold in the United States?
Nilandron’s current commercial availability should be distinguished from its historical FDA approval and Orange Book record. Public information indicates a limited or discontinued commercial role rather than an active branded franchise.
Does nilutamide have generic competition?
Nilutamide is exposed to generic competition because its core exclusivity period has ended. The practical size of that competition is constrained by low demand and substitution by newer therapies.
Can nilutamide be used without orchiectomy?
The FDA-approved Nilandron labeling specifies use with surgical castration. It is not labeled as a stand-alone replacement for castration.[1]
Is nilutamide included in modern prostate-cancer treatment guidelines?
Nilutamide has been displaced in many treatment settings by newer androgen-receptor inhibitors and androgen-synthesis inhibitors. Its use depends on clinical judgment, availability, patient factors, and local guidelines.
Could a shortage make nilutamide commercially attractive again?
A shortage could create temporary demand for an approved generic or alternative supplier. A sustained commercial recovery is unlikely without a new clinical role, a supply disruption affecting competing therapies, or a major change in treatment guidelines.
References
- U.S. Food and Drug Administration. (1996). Nilandron (nilutamide) prescribing information.
- Sanofi. (2023). Universal registration document and annual financial report.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- U.S. Food and Drug Administration. (2024). Generic drug facts and abbreviated new drug application guidance.
